Natera (NASDAQ:NTRA) Given New $405.00 Price Target at JPMorgan Chase & Co.

Key Points

• JPMorgan cut its Natera price target to $405 from $460 but maintained an “overweight” rating, implying about 30% upside from the previous close.
• Natera shares fell 14.6% on Friday to $310.67, amid a quarterly earnings miss: adjusted loss per share was $0.42 versus analysts’ expected $0.28 loss.
• Quarterly revenue rose 34.1% year over year to about $794 million, beating expectations of roughly $708 million. Analysts overall hold a “Moderate Buy” consensus rating, with an average price target of $391.69.

Natera (NASDAQ:NTRA - Get Free Report) had its target price lowered by investment analysts at JPMorgan Chase & Co. from $460.00 to $405.00 in a report released on Friday, Benzinga reports. The brokerage currently has an "overweight" rating on the medical research company's stock. JPMorgan Chase & Co.'s price objective points to a potential upside of 30.36% from the stock's previous close.

NTRA has been the topic of a number of other research reports. Morgan Stanley lifted their target price on shares of Natera from $355.00 to $435.00 and gave the company an "overweight" rating in a research note on Monday, October 12th. Royal Bank Of Canada increased their price target on Natera from $350.00 to $460.00 and gave the stock an "outperform" rating in a research note on Friday, September 25th. Roth Capital began coverage on Natera in a research note on Thursday, October 22nd. They issued a "buy" rating and a $475.00 price target for the company. Guggenheim raised their price target on Natera from $360.00 to $475.00 and gave the company a "buy" rating in a report on Thursday, October 1st. Finally, Citigroup boosted their price objective on Natera from $365.00 to $480.00 and gave the company a "buy" rating in a research report on Tuesday, October 6th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, Natera currently has an average rating of "Moderate Buy" and a consensus target price of $391.69.

Natera Stock Down 14.6%

NASDAQ:NTRA traded down $53.09 during trading hours on Friday, hitting $310.67. 5,775,589 shares of the stock traded hands, compared to its average volume of 1,457,838. Natera has a 1 year low of $181.00 and a 1 year high of $437.41. The company has a market cap of $44.78 billion, a price-to-earnings ratio of -228.43 and a beta of 1.55. The stock has a 50 day moving average price of $380.81 and a 200 day moving average price of $269.30.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings results on Thursday, November 5th. The medical research company reported ($0.42) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.14). The firm had revenue of $793.98 million during the quarter, compared to the consensus estimate of $707.54 million. Natera had a negative return on equity of 11.38% and a negative net margin of 7.11%. The business's revenue for the quarter was up 34.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.64) earnings per share. Equities analysts forecast that Natera will post -1.14 earnings per share for the current fiscal year.

Insider Activity at Natera

In other news, CEO Steven Chapman sold 3,801 shares of the business's stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $411.80, for a total value of $1,565,251.80. Following the transaction, the chief executive officer owned 87,431 shares of the company's stock, valued at approximately $36,004,085.80. The trade was a 4.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Solomon Moshkevich sold 3,419 shares of the business's stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $409.77, for a total transaction of $1,401,003.63. Following the completion of the transaction, the insider directly owned 101,323 shares in the company, valued at $41,519,125.71. This trade represents a 3.26% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 53,573 shares of company stock worth $19,856,400. 5.05% of the stock is currently owned by corporate insiders.

Institutional Trading of Natera

Hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in Natera during the second quarter valued at approximately $2,962,770,000. Bank of America Corp DE bought a new position in Natera in the second quarter worth approximately $199,960,000. Legal & General Group Plc bought a new position in Natera in the second quarter worth approximately $150,143,000. Bank of New York Mellon Corp purchased a new stake in Natera during the second quarter worth $149,278,000. Finally, Avala Global LP purchased a new stake in Natera during the second quarter worth $124,867,000. Hedge funds and other institutional investors own 99.90% of the company's stock.

Key Natera News

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Q3 revenue rose 34.1% year over year to $794 million, beating analyst expectations of about $708 million. Natera also raised its FY2026 sales outlook, supporting its growth outlook. Natera Q3 financial results
• Positive Sentiment: Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could improve access to the test and support adoption of Natera’s oncology products. Medicare coverage for Signatera in HCC
• Negative Sentiment: CEO Steve Chapman is stepping down, creating uncertainty around leadership and the transition plan. The announcement weighed on sentiment despite the company’s revenue growth and improved outlook. Natera announces leadership transition
• Negative Sentiment: Natera’s quarterly loss narrowed from a year earlier, but its reported loss per share of $0.42 was worse than the analyst consensus of a $0.28 loss. That earnings miss appears to have overshadowed the revenue beat. Natera Q3 earnings miss and CEO transition

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.